Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Medpace (MEDP) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Medpace and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) —
What’s Happening:
- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ:MEDP) on behalf of Medpace stockholders. Our investigation concerns whether Medpace has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
- On February 9, 2026, Medpace reported Q4 2025 earnings. While the company posted revenue of $708.5 million and GAAP EPS of $4.67, both exceeding consensus estimates, the results disclosed a Q4 book-to-bill ratio of 1.04, which was lower than Medpace expected. CEO August Troendle acknowledged that cancellations were “the highest in over a year” resulting in the lower-than-anticipated book-to-bill ratio, stating that cancellations “skewed towards metabolic area,” but “no single large project” responsible.
- These disclosures contrasted sharply with statements made during prior earnings calls. On the Q3 2025 call on October 23, 2025, Troendle stated: “Cancellations were well behaved in Q3, permitting record net bookings and a net book-to-bill of 1.20.” On the Q2 call on July 22, 2025, he said cancellations were “down across the pipeline” and predicted a “strong potential for book-to-bills returning to above 1.15x in Q3.” On the Q1 call on April 22, 2025, Troendle projected a “path to improved backlog growth reflected in book-to-bill ratios above 1.15 in Q3 and Q4.”
- The ending backlog stood at approximately $3 billion as of December 31, 2025, reflecting just 4.3% year-over-year growth. Following the Q4 disclosure, Medpace shares fell approximately 15.9% on February 10, 2026. Multiple financial outlets, including Investor’s Business Daily, Seeking Alpha, and GuruFocus, identified the bookings miss as the primary driver of the sell-off.
Next Steps:
- If you purchased or otherwise acquired Medpace shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
